



## Diagnosis of Adverse Reactions to Drugs

Guest Editors:

**Dr. Elena Ramírez**

Clinical Pharmacology, La Paz  
University Hospital—IdiPAZ,  
School of Medicine, Universidad  
Autónoma de Madrid, 28026  
Madrid, Spain

**Dr. Miguel González-Muñoz**

Unit of Immunology, La Paz  
University Hospital, 28046  
Madrid, Spain

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

Adverse drug reactions (ADRs) affect all body organ systems and vary widely in severity. According to the World Health Organization, ADRs are one of the most common causes of morbidity and mortality; thus, they represent a financial burden for health care providers and the pharmaceutical industry. Non-serious ADRs are often resolved rapidly after removal of the casual drug; sometimes, after dose reduction, re-administration of the suspicious drug with the subsequent reappearance of the ADR is the gold standard diagnostic. However, in serious ADRs, which can lead to significant injury to organs/tissues which can be fatal, re-exposure is contraindicated for ethical reasons because its effects can be deadly. Most serious ADRs appear in the post-commercialization period. Therefore, a series of stakeholders would benefit from the development of solid diagnostics for early detection, and improve the forecast of serious ADRs.

Dr. Elena Ramírez

Dr. Miguel González-Muñoz

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Andreas Kjaer

Department of Clinical  
Physiology, Nuclear Medicine &  
PET National University Hospital,  
Rigshospitalet, University of  
Copenhagen, Blegdamsvej 9, DK-  
2100 Copenhagen, Denmark

## Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

## Contact Us

---

*Diagnostics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/diagnostics](http://mdpi.com/journal/diagnostics)  
[diagnostics@mdpi.com](mailto:diagnostics@mdpi.com)  
[X@diagnostic\\_mdpi](https://twitter.com/diagnostic_mdpi)